Uniplan Investment Counsel’s Collegium Pharmaceutical COLL Stock Holding History

Uniplan Investment Counsel’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.21M	Buy	116,362 +47,615	+69%	+$1.63M	0.4%	74
2026 Q1	$2.27M	Sell	68,747 -42,992	-38%	-$1.82M	0.23%	96
2025 Q4	$5.17M	Sell	111,739 -289	-0.3%	-$12.1K	0.52%	54
2025 Q3	$3.92M	Sell	112,028 -18,397	-14%	-$640K	0.38%	67
2025 Q2	$3.86M	Sell	130,425 -12,376	-9%	-$353K	0.39%	62
2025 Q1	$4.26M	Buy	142,801 +797	+0.6%	+$24.4K	0.41%	61
2024 Q4	$4.07M	Sell	142,004 -1,880	-1%	-$62.2K	0.38%	69
2024 Q3	$5.56M	Sell	143,884 -2,491	-2%	-$88.8K	0.49%	51
2024 Q2	$4.71M	Sell	146,375 -543	-0.4%	-$18.8K	0.43%	57
2024 Q1	$5.7M	Sell	146,918 -175	-0.1%	-$6.12K	0.45%	53
2023 Q4	$4.53M	Buy	147,093 +44,477	+43%	+$1.11M	0.34%	63
2023 Q3	$2.32M	Buy	+102,616	New	+$2.34M	0.18%	98

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Uniplan Investment Counsel's COLL Position: Q2 2026 in Review

Uniplan Investment Counsel increased its Collegium Pharmaceutical (COLL) stake by 69% in Q2 2026, buying an estimated $1.63M and bringing the position to 116,362 shares worth $4.21M. The position accounts for 0.4% of the portfolio, ranked #74.

Uniplan Investment Counsel first reported a position in COLL in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.7M in Q1 2024. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Uniplan Investment Counsel held 116,362 shares of Collegium Pharmaceutical worth $4.21M as of Q2 2026.
Uniplan Investment Counsel bought 47,615 Collegium Pharmaceutical shares in Q2 2026, an estimated $1.63M.
Collegium Pharmaceutical made up 0.4% of Uniplan Investment Counsel's portfolio in Q2 2026, its #74 holding.
Uniplan Investment Counsel first reported a position in Collegium Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
Uniplan Investment Counsel's Collegium Pharmaceutical position peaked at $5.7M in Q1 2024.
280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.